Factor II and Factor V Deficiencies: Current Management, Care Gaps and Call to Action for Therapeutic Advances

Our review indicates that currently available therapeutics are largely suboptimal and justify a call to action in order to streamline regulatory pathways for single-factor concentrate development, as well as for the potential evaluation of prophylaxis of coagulation-rebalancing, non-replacement products.